Default Category
-
Dr. Ing. h.c. F. Porsche AG (A): Fiel a la marca
Fear, Jeffrey; Knoop, Carin-IsabelCase HBS-707S13StrategyExamina una de las más importantes decisiones empresariales realizadas en la historia de Porsche, realizadas a principios de 1998: para construir un vehículo utilitario deportivo (SUV) - Cayenne. Después de décadas de depender de uno o dos modelos de coches deportivos y casi en quiebra y perder su independencia en 1993, Porsche tuvo que diversificar sus líneas de productos. También examina las implicaciones de marca de la internacionalización de ...Starting at €8.20
-
Walmart around the World
Alcacer, Juan; Agrawal, Abhishek; Vaish, HarshitCase HBS-714431-EStrategyAfter reaching the limits of its successful expansion in the United States in the early 1990s, Walmart sought growth opportunities in markets abroad. This case describes Walmart's attempts to replicate its successful U.S. business model in Mexico, Canada, Brazil, Argentina, Central America, China, South Korea, Japan, Germany, the U.K., and Africa. Students reflect on the mixed results of these ventures and identify elements in the company's locat...Starting at €8.20
-
Walmart around the World (Spanish version)
Alcacer, Juan; Agrawal, Abhishek; Vaish, HarshitCase HBS-716S11StrategyAfter reaching the limits of its successful expansion in the United States in the early 1990s, Walmart sought growth opportunities in markets abroad. This case describes Walmart's attempts to replicate its successful U.S. business model in Mexico, Canada, Brazil, Argentina, Central America, China, South Korea, Japan, Germany, the U.K., and Africa. Students reflect on the mixed results of these ventures and identify elements in the company's locat...Starting at €8.20
-
MorphoSys AG: The Evolution of a Biotechnology Business Model
Pisano, Gary P.; Johnson, Ryan; Knoop, Carin-IsabelCase HBS-611046-EService and Operations ManagementIn the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently, the company decided to deviate from this model, and attempt to develop its own proprietary products. The case allows analysis of "license vs. vertically integrate" business model de...Starting at €8.20
-
Kl ckner & Co: Steeling for a Digital World
Kominers, Scott Duke; Knoop, Carin-IsabelCase HBS-820035-EEconomicsHoping to get ahead of potential digital disruption at Kl ckner & Co. - one of the world's largest steel and metal distributors - CEO Gisbert R hl set up both kloeckner.i (KCI), an internal transformation arm, and XOM Materials (XOM), an independent industry platform. KCI and XOM sought to digitize the $350 billion materials supply and service chain, and promote greater price transparency and efficiency. However, the materials market traditiona...Starting at €8.20
-
La división de productos domésticos de Hewlett- Packard en Europa (1996-2000)
Arnold, David J.; Knoop, Carin-IsabelCase HBS-507S09Knowledge and CommunicationPara noviembre de 2000, la División de Productos Inicio de Hewlett-Packard (HPD) había sido la venta de su línea de Pabellón de los ordenadores personales en Europa desde hace casi cinco años. Durante ese tiempo, el HPD había entrado y salido de Alemania, tuvo problemas en Francia y el Reino Unido, y reorganizado de manera significativa sus operaciones en Europa dos veces. Algunos de HP sintieron que la operación europea se había convertido en lo...Starting at €8.20
-
inge watertechnologies, GmbH
Nanda, Ramana; Knoop, Carin-Isabel; Mittermaier, MarkusCase HBS-812002-EEntrepreneurshipUsing the financing history and exit choices of a German clean-tech startup as a lens, this case explores the reasons why venture-backed entrepreneurship is much lower in Germany that the US, despite a robust SME sector and large-corporate innovation in Germany. It also shows the tight link between investor incentives and a startup's product market strategy, including differences between "pure-play" VCs and corporate venture capital investors.Starting at €8.20